Stock Price & Analysis

The S1 support level for TSHA Stock is $1.5 ,The R1 resistant level for TSHA Stock is $1.82.

As of the end of day on 2025-02-25, the price of TSHA Stock was $1.7.

The target price for TSHA Stock according to analyst rating is 5.50, with the highest price target at 6.00 and the lowest at 5.00. Analysts have a Moderate Buy rating on TSHA Stock overall.

The market cap of TSHA is $338.2M.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.

TSHA has a total of 52 employees.